Analyst Price Targets — ORIC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 10:20 am | Robert Burns | H.C. Wainwright | $27.00 | $13.50 | TheFly | Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright |
| May 15, 2026 9:09 am | — | Goldman Sachs | $15.00 | $8.34 | TheFly | Oric Pharmaceuticals moved to Buy rating at Goldman Sachs |
| February 24, 2026 3:50 pm | Robert Burns | H.C. Wainwright | $25.00 | $13.27 | TheFly | Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright |
| February 24, 2026 5:34 am | Matthew Biegler | Oppenheimer | $15.00 | $11.71 | StreetInsider | Oppenheimer Reiterates Outperform Rating on ORIC Pharmaceuticals (ORIC) |
| January 7, 2026 10:19 am | Kelsey Goodwin | Piper Sandler | $22.00 | $8.14 | TheFly | Oric Pharmaceuticals initiated with an Overweight at Piper Sandler |
| December 8, 2025 11:15 am | — | Wells Fargo | $25.00 | $11.00 | TheFly | Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo |
| November 14, 2025 3:58 pm | — | H.C. Wainwright | $23.00 | $12.78 | TheFly | Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright |
| September 4, 2025 9:21 am | Brad Canino | Guggenheim | $18.00 | $10.60 | TheFly | Oric Pharmaceuticals assumed with a Buy at Guggenheim |
| May 6, 2025 11:45 am | Matthew Biegler | Oppenheimer | $12.00 | $5.04 | TheFly | Oric Pharmaceuticals price target lowered to $12 from $15 at Oppenheimer |
| September 5, 2024 4:13 pm | Bradley Canino | Stifel Nicolaus | $20.00 | $9.48 | TheFly | Oric Pharmaceuticals initiated with a Buy at Stifel |
Latest News for ORIC
Dimensional Fund Advisors LP increased its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) by 19.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,471,290 shares of the company's stock after acquiring an additional 244,060 shares during the quarter. Dimensional Fund
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 3, 2026 (the “Grant Date”), ORIC granted a total of 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive…
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial Cash and investments of approximately $388 million…
ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat's value is enhanced by a unique royalty-free license and free…
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC SOUTH…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ORIC.
U.S. House Trading
No House trades found for ORIC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.